Extended Data Fig. 6: Anti-SARS-CoV-2 RBD monoclonal antibodies ELISAs.
From: Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
a-e, Graphs show anti-SARS-CoV-2 binding activity of n=458 monoclonal antibodies measured by ELISA against RBD. ELISA half-maximal concentration (EC50) values for all antibodies (a), all clones (b), persisting clones (c), unique clones (d) and singlets (e) isolated from COVID-19 convalescent individuals 1.33 and 6.27 months after infection (left panel) or from vaccinated individuals after prime, or 1.3m or 5m after receiving the second dose of mRNA vaccination (right panel). Each dot represents one antibody. Antibodies isolated from samples without a prime value are shown in black. Red horizontal bars and numbers indicate geometric mean values. Statistical significance was determined by two-tailed Mann-Whitney test (left panels of a, b, d and e), two-tailed Kruskal-Wallis test with subsequent Dunn’s multiple comparisons (right panels of a-e) or by two-tailed Wilcoxon test (left panel of c). All experiments were performed at least twice.
